Page last updated: 2024-12-10

cobalt oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID6432046
MeSH IDM0168594

Synonyms (28)

Synonym
cobalto-cobaltic tetroxide
cobalt oxide (co3o4)
cobaltic-cobaltous oxide
cobalto-cobaltic oxide
cobaltosic oxide
tricobalt tetroxide
tricobalt tetraoxide
einecs 215-157-2
cobalt tetraoxide
cobalt oxide black
oxocobalt; oxo(oxocobaltiooxy)cobalt
cobalt (ii,iii) oxide
einecs 234-334-5
unii-usk772ns56
usk772ns56 ,
ec 215-157-2
cobalt oxide [mart.]
cobaltic-cobaltous oxide [mi]
cobalt (ii,iii) oxide powder, 99% nano
mfcd00010939
cobalt(ii,iii) oxide, 99.7% (metals basis), 2-6 micron powder
cobalt (ii, iii) oxide
cobalt(ii,iii) oxide, 99.7% (metals basis), -400 mesh powder
cobalt(2+);cobalt(3+);oxygen(2-)
UBEWDCMIDFGDOO-UHFFFAOYSA-N
cobalt oxide (mart.)
cobaltum oxydatum
DTXSID801014561 ,

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In vitro bioelution in simulated gastric fluid was the most precise predictor of the difference in the oral RDT lowest observed adverse effect levels of 2 compounds representing the highly and poorly bioaccessible subset of substances."( Bioelution, Bioavailability, and Toxicity of Cobalt Compounds Correlate.
Burzlaff, A; Danzeisen, R; Dourson, M; Verberckmoes, S; Viegas, V; Williams, DL, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" We were able to show a good correlation between high in vitro bioaccessibility with high in vivo bioavailability and subsequent high in vivo toxicity; consequently, low in vitro bioaccessibility correlated well with low in vivo bioavailability and low in vivo toxicity."( Bioelution, Bioavailability, and Toxicity of Cobalt Compounds Correlate.
Burzlaff, A; Danzeisen, R; Dourson, M; Verberckmoes, S; Viegas, V; Williams, DL, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's67 (100.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other67 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]